FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      
           
This page is updated frequently with new Rheumatoid Arthritis-related patent applications. Subscribe to the Rheumatoid Arthritis RSS feed to automatically get the update: related Rheumatoid RSS feeds. RSS updates for this page: Rheumatoid Arthritis RSS RSS


Phototherapy device

Date/App# patent app List of recent Rheumatoid Arthritis-related patents
07/24/14
20140206694
 Heterocyclic compounds and their uses patent thumbnailHeterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
07/24/14
20140206680
 Substituted 6-aza-isoindolin-1-one derivatives patent thumbnailSubstituted 6-aza-isoindolin-1-one derivatives
Disclosed are compounds of formula 1, and pharmaceutically acceptable salts thereof, wherein g, p, r1, r2, r3a, r4, and r5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of syk is indicated..
07/17/14
20140200635
 Phototherapy device patent thumbnailPhototherapy device
Provided is a phototherapy device which enables a sufficient amount of light to reach a deep tissue to achieve a satisfactory therapy while preventing the increase in the skin temperature of an affected part, and which can achieve a comfortable therapy. The present invention provides a phototherapy device comprising a sheet-like member having a first surface on which an affected part is to be arranged and a surface light source for emitting light toward the sheet-like member, wherein the first surface is formed in an uneven shape so as to provide multiple grooves.
07/17/14
20140200260
 Methods for determining and inhibiting rheumatoid arthritis associated with the braf oncogene in a subject patent thumbnailMethods for determining and inhibiting rheumatoid arthritis associated with the braf oncogene in a subject
The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the braf oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the braf oncogene; and culturing the sample in the presence of the agent and determining whether braf oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the braf oncogene.. .
07/17/14
20140200245
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
07/17/14
20140199414
 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport patent thumbnailKrill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
07/10/14
20140194413
 Inhibitors of bruton's tyrosine kinase patent thumbnailInhibitors of bruton's tyrosine kinase
Wherein, variables r, x, y1, y2, y2′, y3, y4, n and m are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
07/10/14
20140194343
 Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases patent thumbnailCtrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
[solution] a pharmaceutical composition containing ctrp6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided..
07/10/14
20140194308
 Use of myelin basic protein as a novel genetic factor for rheumatoid arthritis patent thumbnailUse of myelin basic protein as a novel genetic factor for rheumatoid arthritis
A method of testing for rheumatoid arthritis, comprising detecting an autoantibody to myelin basic protein in a biological sample from a subject. A test kit for rheumatoid arthritis, comprising myelin basic protein.
07/10/14
20140193411
 Multimeric constructs patent thumbnailMultimeric constructs
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
07/10/14
20140193366
Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis
A mir-323-3p inhibitor is provided for the prevention or therapy of rheumatoid arthritis, comprising a sequence capable of forming a hybrid to mir-323-3p as an oligonucleotide or a vector from which such oligonucleotide is transcribed, or as a mirna decoy or sponge.. .
06/26/14
20140179750
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
The disclosure relates to prostaglandin receptor ep2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which ep2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof..
06/26/14
20140178509
Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—free-b-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the cox-2 and 5-lo pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (cox-2) and 5-lipoxygenase (5-lo) enzymes, and reducing cox-2 mrna production.
06/26/14
20140178389
Il-1 binding proteins
The disclosure provides binding proteins that specifically bind to il-1α and il-1β. These binding proteins can be organized into dvd-igs.
06/19/14
20140171469
Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
06/19/14
20140171437
Oxazole derivatives useful as inhibitors of faah
The present invention is directed to certain oxazole derivatives which are useful as inhibitors of fatty acid amide hydrolase (faah). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, alzeimer disease, and parkinson's disease..
06/19/14
20140170683
Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (ra), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (acpas). The present invention also provides methods for detecting rheumatoid factor (rf) using novel rf detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as ra.
06/12/14
20140162983
Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
The present invention provides novel pyrimidine and pyridine compounds according to formula (i), formula (ii), formula (iii), formula (iv) and formula (v) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of bruton's tyrosine kinase..
06/05/14
20140155461
Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
The present invention relates to methods for identifying agents capable of inhibiting the expression or activity of proteins involved in the processes modulating osteoclastogenesis, which inhibition is useful in the prevention and/or treatment of bone and joint degenerative diseases and diseases involving aberrant activity or differentiation of osteoclasts. In particular, the present invention provides methods for identifying agents for use in the prevention and/or treatment of rheumatoid arthritis..
06/05/14
20140155377
3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
(wherein r1, r2, r3, r4, r5, r6, r7, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor.
06/05/14
20140154247
Biological markers and methods for predicting response to b-cell antagonists
Biological markers that predict patient responsiveness to b-cell antagonists are provided. Also provided are methods of using such biological markers.
05/29/14
20140148474
Aminopyrimidines as syk inhibitors
The present invention provides novel pyrimidine amines of formula i which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd, rheumatoid arthritis and cancer.. .
05/29/14
20140148459
Matrix metalloproteinase inhibitors
This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, copd, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and pounds.. .
05/29/14
20140148405
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
05/29/14
20140147453
Fusion peptide comprising dhfas-1 domain and mmp substrate and use thereof for preventing and treating rheumatoid arthritis
The present invention relates to a fusion peptide comprising dhfas-1 domain and mmp substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhfas-1 domain which is the fourth fas-1 domain of βig-h3 lacking h1 and h2 regions; b) a mmp (matrix metalloproteinase) substrate; and c) a peptide comprising rgd motif and an use thereof for preventing and treating inflammatory disease.
05/22/14
20140142135
4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
R1 and r6 may have the meanings as described in claim 1, as well as medicaments which contain these compounds. Further, the invention relates to methods of treating a disease selected from asthma, copd, allergic rhinitis, adult respiratory distress syndrome, bronchitis, allergic dermatitis, contact dermatitis, idiopathic thrombocytopenic purpura, rheumatoid arthritis and allergic rhinoconjunctivitis by administrating an appropriate amount of a compound of formula 1 to a patient in need thereof..
05/22/14
20140142109
Antifolate combinations
The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds.
05/22/14
20140142100
New macrolides and their use
The use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (pde4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (copd), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer..
05/22/14
20140141077
Composition for use in treating and preventing inflammation related disorder
The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
05/22/14
20140141018
Antagonist anti-il-7 receptor antibodies and methods
The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (il-7r). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids.
05/15/14
20140134102
Fucoidans as ligands for the diagnosis of degenerative pathologies
The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and mri.
05/08/14
20140128467
Methods of treatment using a bcat1 inhibitor
The present invention is directed to methods of using inhibitors of the cytosolic form of bcat in the treatment of cancer, rheumatoid arthritis, and bone disease.. .
05/08/14
20140128341
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
05/08/14
20140127720
Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
In one or more embodiments, the present invention provides a novel biomarker which provides a link between a distinct clinical phenotype and a biochemical effect of an autoantibody on an enzyme implicated in disease pathogenesis. In particular, the present invention provides an isolated or purified human autoantibody to pad3 protein.
05/08/14
20140127295
Compositions, process of preparation of said compositions and method of treating inflammatory diseases
The present disclosure describes a composition and a kit having a plurality of compounds for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as rheumatoid arthritis (ra). The disclosure also relates to a process of obtaining the composition and the method of treating diseases by administration of the compositions..
05/01/14
20140121204
Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis, lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.
05/01/14
20140120109
Human antibodies to human tnf-like ligand 1a (tl1a)
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
05/01/14
20140120101
Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of both the heterodimeric il12 and il23 receptors. The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifnγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifnγ production, il12 and/il23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
05/01/14
20140120060
Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
Provided herein are methods, kits, and pharmaceutical compositions that include a pi3 kinase inhibitor for treating rheumatoid arthritis or asthma.. .
04/24/14
20140113867
Apls for treating arthritis
One embodiment of a therapeutic composition comprises one or more apls, e.g., apl a12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of a12 analog peptide.
04/24/14
20140112935
Antibodies to interleukin-6 and use thereof
The present disclosure provides antibodies that bind to human interleukin-6 (il6). The antibodies can modulate il6 signaling and thus used in treatment or prevention of il6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (ra), angiogenesis, and cancer..
04/17/14
20140107322
Methods of use of soluble cd24 for therapy of rheumatoid arthritis
Provided herein is a cd24 protein. The cd24 protein may include mature human or mouse cd24, as well as a n- or c-terminally fused portion of a mammalian immunoglobulin..
04/17/14
20140107097
Heteroaryl linked quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/17/14
20140107096
Heteroaryl linked quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/17/14
20140107094
Methylene linked quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/17/14
20140106381
Method for the diagnosis of rheumatoid arthritis
The present invention refers to the use of citrullinated synthetic peptides for the diagnosis of rheumatoid arthritis (ra).. .
04/10/14
20140100250
Pyridyl aminopyridines as syk inhibitors
The present invention provides novel pyrimidine amines of formula i which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd, rheumatoid arthritis, and cancer.. .
04/10/14
20140099708
Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of both the heterodimeric il12 and il23 receptors. The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifnγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifnγ production, il12 and/il23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
04/10/14
20140099323
Methods for treatment of inflammatory diseases
It provides methods and pharmaceutical compositions comprising antagonists to the protein bile salt-stimulated lipase (bssl) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising bssl antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis.
03/27/14
20140088415
Medical imaging devices, methods, and systems
The disclosed subject matter includes devices, methods, and systems for generating optical tomographic data including volumetric and surface geometric data. The disclosed subject matter also includes devices, methods, and systems for generating optical tomographic data for purposes of diagnosing rheumatoid arthritis..
03/27/14
20140086895
Methods and pharmaceutical compositions for the treatment of autoimmune diseases
The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune diseases, especially rheumatoid arthritis. More particularly, the present invention relates to an a-enolase polypeptide for use in the prophylactic treatment of an autoimmune disease in a subject in need thereof..
03/20/14
20140080879
Factor viia inhibitor
The present invention relates to novel inhibitors of factors viia, ixa, xa, xia, in particular factor viia, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed..
03/20/14
20140079719
Il-17 antagonistic antibodies
An il-17 binding molecule, in particular an antibody to human il-17, more preferably a human antibody to human il-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an il-17 mediated disease or disorder, e.g. Rheumatoid arthritis..
03/20/14
20140079708
Antibody molecule for human gm-csf receptor alpha
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (gm-csfrα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g.
03/20/14
20140079699
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis..
03/13/14
20140073572
Targeting complement factor h for treatment of diseases
The invention provides a cr2-fh molecule comprising a cr2 portion comprising cr2 protein or a fragment thereof and a fh portion comprising a factor h protein or a fragment thereof, and pharmaceutical compositions comprising a cr2-fh molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion..
03/13/14
20140072576
Chemokine receptor antagonists and use thereof
Wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against cxcr4 and is therefore useful as a preventive and/or therapeutic agent for cxcr4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy..
03/13/14
20140072573
Method of treating rheumatoid arthritis
Treating the patient until a basal level of soluble ve-cadherin is reached.. .
03/13/14
20140072551
Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) p-selectin. The p-selectin antibodies prevent p-selectin from binding to its cognate receptor.
03/06/14
20140066520
Novel anti-inflammatory cyclooxygenase inhibitors
Disclosed is a pharmaceutical composition including a therapeutic quantity of a cox-2 inhibitor having an ic50-whma cox-2/cox-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition..
02/27/14
20140057877
Therapeutic polyamine compositions and their synthesis
This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and ppar partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.
02/27/14
20140056888
High concentration antibody formulations
The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component c5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions.
02/27/14
20140056886
Humanized anti-il-20 antibody and uses thereof
Humanized antibodies specific to human interleukin 20 (il-20) and uses thereof in treating diseases associated with the il-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.. .
02/27/14
20140056885
Subcutaneously administered anti-il-6 receptor antibody
The present application discloses methods for treating an il-6-mediated disorder such as rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia), systemic jia (sjia), polyarticular course jia (pcjia), systemic sclerosis, or giant cell arteritis (gca), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-il-6r antibody). In particular, it relates to identification of a fixed dose of anti-il-6r antibody, e.g.
02/27/14
20140056884
Subcutaneously administered anti-il-6 receptor antibody
The present application discloses methods for treating an il-6-mediated disorder such as rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia), systemic jia (sjia), polyarticular course jia (pcjia), systemic sclerosis, or giant cell arteritis (gca), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-il-6r antibody). In particular, it relates to identification of a fixed dose of anti-il-6r antibody, e.g.
02/27/14
20140056883
Subcutaneously administered anti-il-6 receptor antibody
The present application discloses methods for treating an il-6-mediated disorder such as rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia), systemic jia (sjia), polyarticular course jia (pcjia), systemic sclerosis, or giant cell arteritis (gca), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-il-6r antibody). In particular, it relates to identification of a fixed dose of anti-il-6r antibody, e.g.
02/27/14
20140056809
Treatment and diagnosis of macrophage mediated disease
Where the group ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group x comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, x comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis..
02/20/14
20140051655
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment.
02/20/14
20140050696
Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent represent additional aspects of the invention.
02/13/14
20140045840
Compounds and methods for kinase modulation, and indications therefor
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on fms protein kinase, or on fms and kit protein kinase, or on fms and flt-3 protein kinase.
02/06/14
20140038987
Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of formula (ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the s1p1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, microbial infections or diseases and viral infections or diseases..
02/06/14
20140038944
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .


Popular terms: [SEARCH]

Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4263

4029

1 - 1 - 72